Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 230

1.

Reduced-dose intramuscular ketamine for severe agitation in an academic emergency department.

O'Brien ME, Fuh L, Raja AS, White BA, Yun BJ, Hayes BD.

Clin Toxicol (Phila). 2019 Jul 23:1-5. doi: 10.1080/15563650.2019.1643468. [Epub ahead of print]

PMID:
31335216
2.

Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers.

Stewart A, Coker EA, Pölsterl S, Georgiou A, Minchom AR, Carreira S, Cunningham D, O'Brien ME, Raynaud FI, de Bono JS, Al-Lazikani B, Banerji U.

Mol Cancer Ther. 2019 Aug;18(8):1396-1404. doi: 10.1158/1535-7163.MCT-18-0727. Epub 2019 Jul 1.

PMID:
31262731
3.

Loss of skin elasticity is associated with pulmonary emphysema, biomarkers of inflammation, and matrix metalloproteinase activity in smokers.

O'Brien ME, Chandra D, Wilson RC, Karoleski CM, Fuhrman CR, Leader JK, Pu J, Zhang Y, Morris A, Nouraie S, Bon J, Urban Z, Sciurba FC.

Respir Res. 2019 Jun 24;20(1):128. doi: 10.1186/s12931-019-1098-7.

4.

BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications.

Weathington N, O'Brien ME, Radder J, Whisenant TC, Bleecker ER, Busse WW, Erzurum SC, Gaston B, Hastie AT, Jarjour NN, Meyers DA, Milosevic J, Moore WC, Tedrow JR, Trudeau JB, Wong HP, Wu W, Kaminski N, Wenzel SE, Modena BD.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):837-856. doi: 10.1164/rccm.201811-2221OC.

PMID:
31161938
5.

Age-related cardiovascular outcomes in older adults receiving epinephrine for anaphylaxis in the emergency department.

O'Brien ME, Koehl JL, Raja AS, Erickson TB, Hayes BD.

J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2888-2890. doi: 10.1016/j.jaip.2019.04.040. Epub 2019 May 10. No abstract available.

PMID:
31078763
6.

Prolonged Cold Ischemia Induces Necroptotic Cell Death in Ischemia-Reperfusion Injury and Contributes to Primary Graft Dysfunction after Lung Transplantation.

Wang X, O'Brien ME, Yu J, Xu C, Zhang Q, Lu S, Liang L, An X, McDyer JF, Mallampalli RK.

Am J Respir Cell Mol Biol. 2019 Aug;61(2):244-256. doi: 10.1165/rcmb.2018-0207OC.

PMID:
30742487
7.

FBXO17 promotes cell proliferation through activation of Akt in lung adenocarcinoma cells.

Suber TL, Nikolli I, O'Brien ME, Londino J, Zhao J, Chen K, Mallampalli RK, Zhao Y.

Respir Res. 2018 Oct 25;19(1):206. doi: 10.1186/s12931-018-0910-0.

8.

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J.

Cancer Chemother Pharmacol. 2018 Nov;82(5):757-766. doi: 10.1007/s00280-018-3661-1. Epub 2018 Aug 7.

9.

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.

Gridelli C, Chen T, Ko A, O'Brien ME, Ong TJ, Socinski MA, Postmus PE.

Drug Des Devel Ther. 2018 May 24;12:1445-1451. doi: 10.2147/DDDT.S155750. eCollection 2018.

10.

Wife Caregiver Experiences in the Patient with Prostate Cancer at Home.

O'Brien ME, Steele NM.

Urol Nurs. 2017 Jan-Feb;37(1):37-44.

PMID:
29240364
11.

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U.

PLoS One. 2017 Oct 5;12(10):e0186106. doi: 10.1371/journal.pone.0186106. eCollection 2017.

12.

Risk factors for totally implantable venous access device-associated complications in cystic fibrosis.

McCarthy C, O'Carroll O, O'Brien ME, McEnery T, Franciosi A, Gunaratnam C, McElvaney NG.

Ir J Med Sci. 2018 May;187(2):429-434. doi: 10.1007/s11845-017-1672-2. Epub 2017 Aug 15.

PMID:
28812224
13.

Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.

Hmmier A, O'Brien ME, Lynch V, Clynes M, Morgan R, Dowling P.

BBA Clin. 2017 Mar 6;7:97-104. doi: 10.1016/j.bbacli.2017.03.001. eCollection 2017 Jun.

14.

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA.

Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17.

PMID:
28214659
15.

Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.

Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA.

Curr Probl Cancer. 2017 Mar - Apr;41(2):111-124. doi: 10.1016/j.currproblcancer.2016.12.002. Epub 2016 Dec 23. Review.

PMID:
28214087
16.

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma.

Minchom A, Punwani R, Filshie J, Bhosle J, Nimako K, Myerson J, Gunapala R, Popat S, O'Brien ME.

Eur J Cancer. 2016 Jul;61:102-10. doi: 10.1016/j.ejca.2016.03.078. Epub 2016 May 6.

PMID:
27156228
17.

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.

Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, Yap TA, Du Y, Vlahos I, deSouza NM.

Eur J Cancer. 2016 May;59:65-78. doi: 10.1016/j.ejca.2016.02.017. Epub 2016 Mar 24. Review.

PMID:
27016624
18.

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Shah MH, Lorigan P, O'Brien ME, Fossella FV, Moore KN, Bhatia S, Kirby M, Woll PJ.

Invest New Drugs. 2016 Jun;34(3):290-9. doi: 10.1007/s10637-016-0336-9. Epub 2016 Mar 9.

19.

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.

Kumar R, Lu SK, Minchom A, Sharp A, Davidson M, Gunapala R, Yap TA, Bhosle J, Popat S, O'Brien ME.

Cancer Chemother Pharmacol. 2016 Feb;77(2):375-83. doi: 10.1007/s00280-015-2950-1. Epub 2015 Dec 26.

PMID:
26706729
20.

The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling.

O'Dwyer CA, O'Brien ME, Wormald MR, White MM, Banville N, Hurley K, McCarthy C, McElvaney NG, Reeves EP.

J Immunol. 2015 Oct 15;195(8):3628-41. doi: 10.4049/jimmunol.1500038. Epub 2015 Sep 14.

Supplemental Content

Loading ...
Support Center